Dai Shimizu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dai Shimizu has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Kentaroh Miyoshi
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
6 shared publications - Seiichiro Sugimoto
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
6 shared publications - Shinichi Toyooka
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan
6 shared publications - Mikio Okazaki
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
5 shared publications - Shin Tanaka
Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
4 shared publications - Haruchika Yamamoto
Department of General Thoracic and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; Department of General Thoracic Surgery and Organ Transplant Center, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
3 shared publications
Latest Publications
- 7 October 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (6) , 1235-1242
Survival and functional outcomes of single lung transplantation in secondary pulmonary hypertension
- 7 October 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (6) , 1235-1242
Survival and functional outcomes of single lung transplantation in secondary pulmonary hypertension
- 16 October 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (2) , 284-292
In vivo lung perfusion for prompt recovery from primary graft dysfunction after lung transplantation
- 16 October 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (2) , 284-292
In vivo lung perfusion for prompt recovery from primary graft dysfunction after lung transplantation
- 31 August 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 629, 86-94
Inhibiting S100A8/A9 attenuates airway obstruction in a mouse model of heterotopic tracheal transplantation
- 31 August 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 629, 86-94
Inhibiting S100A8/A9 attenuates airway obstruction in a mouse model of heterotopic tracheal transplantation
- Open Access
- 7 April 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (4) , S378-S379
Pulmonary Alveolar Proteinosis After Lung Transplantation
- 7 April 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (4) , S378-S379
Open AccessPulmonary Alveolar Proteinosis After Lung Transplantation
- Open Access
- 7 April 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (4) , S106-S107
The Percentage of Low Attenuation Area on Computed Tomography to Detect Chronic Lung Allograft Dysfunction After Bilateral Lung Transplantation
- 7 April 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (4) , S106-S107
Open AccessThe Percentage of Low Attenuation Area on Computed Tomography to Detect Chronic Lung Allograft Dysfunction After Bilateral Lung Transplantation
- 31 March 2022
- Published by Springer Nature in Surgery Today
- Vol. 52 (11) , 1540-1550
Paediatric lung transplantation: the impact of age on the survival
Objectives We herein review the outcomes of paediatric lung transplantation (LTx) and analyse subgroups divided by age. Methods We retrospectively reviewed 43 consecutive paediatric LTx recipients (< 18 years old: cadaveric LTx [n = 9], living-donor lobar LTx [n = 34]). We also analysed subgroups of patients 1–6 years old (n = 10) and 7–17 years old (n = 33). Results The 1-, 5- and 10-year overall survival (OS) rates in paediatric recipients were 93%, 82% and 67%, respectively. The 1-, 5- and 10-year graft dysfunction (GD)-free survival rates in paediatric recipients were 85%, 59% and 31%, respectively. The 1- and 5-year OS in the 1- to 6-year-old vs. 7- to 17-year-old groups were 70% vs. 100% and 48% vs. 93%, respectively (p < 0.0001). The 1- and 5-year GD-free survival rates in the 1- to 6-year-old vs. 7- to 17-year-old groups were 60% vs. 93% and 24% vs. 69%, respectively (p = 0.024). The 1- to 6-year-old group showed higher rates of non-standard LTx (p = 0.0001), interstitial pneumonia (p = 0.004) and ventilator dependency (p = 0.007) than the 7- to 17-year-old group. Conclusion Paediatric recipients under 7 years old seemed to have a higher risk of mortality and GD than those 7 years old and older.
- 31 March 2022
- Published by Springer Nature in Surgery Today
- Vol. 52 (11) , 1540-1550
Paediatric lung transplantation: the impact of age on the survival
Objectives We herein review the outcomes of paediatric lung transplantation (LTx) and analyse subgroups divided by age. Methods We retrospectively reviewed 43 consecutive paediatric LTx recipients (< 18 years old: cadaveric LTx [n = 9], living-donor lobar LTx [n = 34]). We also analysed subgroups of patients 1–6 years old (n = 10) and 7–17 years old (n = 33). Results The 1-, 5- and 10-year overall survival (OS) rates in paediatric recipients were 93%, 82% and 67%, respectively. The 1-, 5- and 10-year graft dysfunction (GD)-free survival rates in paediatric recipients were 85%, 59% and 31%, respectively. The 1- and 5-year OS in the 1- to 6-year-old vs. 7- to 17-year-old groups were 70% vs. 100% and 48% vs. 93%, respectively (p < 0.0001). The 1- and 5-year GD-free survival rates in the 1- to 6-year-old vs. 7- to 17-year-old groups were 60% vs. 93% and 24% vs. 69%, respectively (p = 0.024). The 1- to 6-year-old group showed higher rates of non-standard LTx (p = 0.0001), interstitial pneumonia (p = 0.004) and ventilator dependency (p = 0.007) than the 7- to 17-year-old group. Conclusion Paediatric recipients under 7 years old seemed to have a higher risk of mortality and GD than those 7 years old and older.
- 7 January 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 114 (4) , e245-e247
Acute Pulmonary Edema Due to Arteriovenous Shunt Placement After Lung Transplantation
- 7 January 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 114 (4) , e245-e247
Acute Pulmonary Edema Due to Arteriovenous Shunt Placement After Lung Transplantation
- 25 October 2021
- Published by Springer Nature in Surgery Today
- Vol. 52 (4) , 697-704
Effect of preoperative long-term use of corticosteroids on the development of post-transplant lymphoproliferative disorders after lung transplantation: a single-center experience in Japan
Purpose Post-transplant lymphoproliferative disorder (PTLD) is a major complication of lung transplantation (LTx). However, few studies on PTLD in Asian populations have been reported. We explored the characteristics of Japanese PTLD cases after LTx. Methods We retrospectively reviewed 195 cases of LTx at our institute. We summarized the clinical experiences of 7 PTLD cases and analyzed the patient characteristics and survival outcomes of patients with (n = 7) and without (n = 188) PTLD. Results All PTLD patients were taking corticosteroids preoperatively (p = 0.0030), and the duration of preoperative corticosteroid therapy was significantly longer in the PTLD group (p = 0.0064) than in the non-PTLD group. The overall survival after LTx was significantly worse in the PTLD group (p = 0.027) than in the non-PLTD group. Among the three patients who died within 1 year after the PTLD onset, two died of opportunistic infections without residual PTLD lesions. Chronic lung allograft dysfunction (CLAD) or bronchiolitis obliterans at an autopsy were diagnosed after PTLD treatment in four cases. Conclusions Long-term preoperative corticosteroid therapy may be a risk factor for PTLD after LTx. Opportunistic infections are lethal complications of PTLD, regardless of the effectiveness of PTLD treatment. CLAD occurs at a high rate after PTLD treatment, and close monitoring is required.
- 25 October 2021
- Published by Springer Nature in Surgery Today
- Vol. 52 (4) , 697-704
Effect of preoperative long-term use of corticosteroids on the development of post-transplant lymphoproliferative disorders after lung transplantation: a single-center experience in Japan
Purpose Post-transplant lymphoproliferative disorder (PTLD) is a major complication of lung transplantation (LTx). However, few studies on PTLD in Asian populations have been reported. We explored the characteristics of Japanese PTLD cases after LTx. Methods We retrospectively reviewed 195 cases of LTx at our institute. We summarized the clinical experiences of 7 PTLD cases and analyzed the patient characteristics and survival outcomes of patients with (n = 7) and without (n = 188) PTLD. Results All PTLD patients were taking corticosteroids preoperatively (p = 0.0030), and the duration of preoperative corticosteroid therapy was significantly longer in the PTLD group (p = 0.0064) than in the non-PTLD group. The overall survival after LTx was significantly worse in the PTLD group (p = 0.027) than in the non-PLTD group. Among the three patients who died within 1 year after the PTLD onset, two died of opportunistic infections without residual PTLD lesions. Chronic lung allograft dysfunction (CLAD) or bronchiolitis obliterans at an autopsy were diagnosed after PTLD treatment in four cases. Conclusions Long-term preoperative corticosteroid therapy may be a risk factor for PTLD after LTx. Opportunistic infections are lethal complications of PTLD, regardless of the effectiveness of PTLD treatment. CLAD occurs at a high rate after PTLD treatment, and close monitoring is required.
- 21 June 2021
- Published by Wiley in International Journal of Cancer
- Vol. 149 (8) , 1593-1604
Oncogenic potential of human pluripotent stem cell‐derived lung organoids with HER2 overexpression
Lung adenocarcinoma (LUAD) is the most common types among lung cancers generally arising from terminal airway and understanding of multistep carcinogenesis is crucial to develop novel therapeutic strategy for LUAD. Here we used human induced pluripotent stem cells (hiPSCs) to establish iHER2‐hiPSCs in which doxycycline induced the expression of the oncoprotein human epidermal growth factor receptor 2 (HER2)/ERBB2. Lung progenitors that differentiated from iHER2‐hiPSCs, which expressed NKX2‐1/TTF‐1 known as a lung lineage maker, were cocultured with human fetal fibroblast and formed human lung organoids (HLOs) comprising alveolar type 2‐like cells. HLOs that overexpressed HER2 transformed to tumor‐like structures similar to atypical adenomatous hyperplasia, which is known for lung precancerous lesion and upregulated the activities of oncogenic signaling cascades such as RAS/RAF/MAPK and PI3K/AKT/mTOR. The degree of morphological irregularity and proliferation capacity were significantly higher in HLOs from iHER2‐hiPSCs. Moreover, the transcriptome profile of the HLOs shifted from a normal lung tissue‐like state to one characteristic of clinical LUAD with HER2 amplification. Our results suggest that hiPSC‐derived HLOs may serve as a model to recapitulate the early tumorigenesis of LUAD and would provide new insights into the molecular basis of tumor initiation and progression.
- 21 June 2021
- Published by Wiley in International Journal of Cancer
- Vol. 149 (8) , 1593-1604
Oncogenic potential of human pluripotent stem cell‐derived lung organoids with HER2 overexpression
Lung adenocarcinoma (LUAD) is the most common types among lung cancers generally arising from terminal airway and understanding of multistep carcinogenesis is crucial to develop novel therapeutic strategy for LUAD. Here we used human induced pluripotent stem cells (hiPSCs) to establish iHER2‐hiPSCs in which doxycycline induced the expression of the oncoprotein human epidermal growth factor receptor 2 (HER2)/ERBB2. Lung progenitors that differentiated from iHER2‐hiPSCs, which expressed NKX2‐1/TTF‐1 known as a lung lineage maker, were cocultured with human fetal fibroblast and formed human lung organoids (HLOs) comprising alveolar type 2‐like cells. HLOs that overexpressed HER2 transformed to tumor‐like structures similar to atypical adenomatous hyperplasia, which is known for lung precancerous lesion and upregulated the activities of oncogenic signaling cascades such as RAS/RAF/MAPK and PI3K/AKT/mTOR. The degree of morphological irregularity and proliferation capacity were significantly higher in HLOs from iHER2‐hiPSCs. Moreover, the transcriptome profile of the HLOs shifted from a normal lung tissue‐like state to one characteristic of clinical LUAD with HER2 amplification. Our results suggest that hiPSC‐derived HLOs may serve as a model to recapitulate the early tumorigenesis of LUAD and would provide new insights into the molecular basis of tumor initiation and progression.
- Open Access
- 1 August 2020
- Published by Elsevier in Trauma & Case Reports
- Vol. 28, 100319
Diagnostic and therapeutic role of endoscopic retrograde pancreatography and stent placement for grade IV blunt pancreatic trauma: A case report
- 1 August 2020
- Published by Elsevier in Trauma & Case Reports
- Vol. 28, 100319
Open AccessDiagnostic and therapeutic role of endoscopic retrograde pancreatography and stent placement for grade IV blunt pancreatic trauma: A case report